Menu

Personalized cancer vaccine cuts melanoma recurrence or death risk by 42% in phase 3 trial

Reading 0:00
15s threshold

Pretty encouraging results from ESMO. Adding a personalized mRNA vaccine to immunotherapy reduced the risk of melanoma recurrence or death by 42%.

Still waiting on peer-reviewed results and longer follow-up, but this could be a big development for cancer treatment.

Source: https://www.oncologynewscentral.com/melanoma-and-skin-cancer/personalized-mrna-vaccine-reduces-melanoma-recurrence-risk

submitted by /u/Postcall_Dogtor
[link] [comments]